Netherlands· NL-c1e6b66b100c

Aumseqa 55 mg filmomhulde tablet

A aumolertinib product containing aumolertinibmesilaat, registered in Netherlands by SFL Pharmaceuticals Deutschland GmbH. The same ATC class is registered in 8 of our 19 countries.

ATC L01EB11

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about aumolertinibmesilaatAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Aumolertinib is registered in 8 of 19 countries.

Countries holding a registration under ATC L01EB11 (aumolertinib), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
5 of them publish a price we can compare per daily dose

Search aumolertinib products by name

Aumolertinib · ATC L01EB11

8 / 19 countries

Belgiumprice
Czechiaprice
Denmark
Finlandprice
Icelandprice
Ireland
Netherlands
Polandprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)

Active substance: AUMOLERTINIBMESILAAT
Manufacturer: SFL Pharmaceuticals Deutschland GmbH
Country: Netherlands (NL)
ATC code: L01EB11
ATC class: Aumolertinib
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/25/2006

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Aumolertinib in 7 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All aumolertinib products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/aae757ed-9028-422a-87ab-afdbeb3bc41a
GET /v1/drugs/aae757ed-9028-422a-87ab-afdbeb3bc41a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/aumseqa-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Aumolertinib",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp130780",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "IJZEROXIDE GEEL (E 172)",
    "LACTOSE 0-WATER",
    "MACROGOL",
    "MACROGOL 3350",
    "MAGNESIUMSTEARAAT (E 470b)",
    "NATRIUMSTEARYLFUMARAAT",
    "NATRIUMZETMEELGLYCOLAAT",
    "POLYVINYLALCOHOL (E 1203)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "AUMOLERTINIBMESILAAT"
  ],
  "leaflet_url": null,
  "authorised_at": "2026/02/12",
  "procedure_number": "EMEA/H/C/006069",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/25/2006",
  "additional_monitoring": "Y"
}

API reference MCP server Plans

See everything about aumolertinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console